Neuro

NanoString Technologies to Present Portfolio of Cutting-edge Brain Research and Novel Spatial Biology Applications for Neuroscience

Retrieved on: 
Thursday, November 9, 2023

NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.

Key Points: 
  • NanoString Technologies, a leading provider of life sciences tools for discovery and translational research, announced today it will present at the Society for Neuroscience (SfN) annual meeting a large body of new brain research powered by its industry-leading digital spatial profiling and spatial imaging platforms.
  • The presentation will be delivered by Caleb Stokes, M.D., Ph.D. of the University of Washington at NanoSymposium (NANO22.08) on Sunday, Nov. 12, from 2:45-3:00 PM EST.
  • “With this unprecedented capability, researchers will gain critical insights into single cell signaling for healthy and diseased brain tissue.
  • The opportunity for future patient benefit is enormous,” said Brad Gray, President and CEO of NanoString.

Cordance Medical Announces Agreement with Stanford Medicine's Airan and Williams Labs for Precision Neuropsychiatry with Ultrasonic Drug Uncaging Technology

Retrieved on: 
Thursday, December 7, 2023

MOUNTAIN VIEW, Calif., Dec. 7, 2023 /PRNewswire/ -- Cordance Medical, a pioneering medical technology company focused on non-invasive brain treatments, is pleased to announce a new strategic agreement with Stanford Medicine, working with radiologist Dr. Raag Airan, Assistant Professor, and neurologist-psychiatrist Dr. Nolan Williams, Associate Professor, Stanford Medicine. This collaboration will combine Cordance's breakthrough NeuroAccess™ device with Dr. Airan's novel nanoparticle drug development to establish a new standard for precision medicine in neurology and psychiatry. Dr. Airan is also an Advisor with Cordance Medical.

Key Points: 
  • The combined expertise of Cordance and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
  • This method enables focal noninvasive drug delivery with the Airan Lab's pioneering technology of Ultrasonic Drug Uncaging, leveraging the capabilities of NeuroAccess beyond its original function of blood-brain barrier (BBB) opening.
  • "With this agreement, we're taking a critical step forward in the field of precision neuropsychiatry," said Ryan Dittamore, CEO of Cordance.
  • Airan and Williams at Stanford Medicine said, "Our labs have made significant strides in developing ultrasonic drug uncaging using drug-loaded nanoparticles that can be triggered using short, low-intensity ultrasound pulses.

Evolution Optiks Successfully Completes Data Collection in Clinical Study of Neuro-Optical Testing Device

Retrieved on: 
Tuesday, December 5, 2023

CHRIST CHURCH, Barbados, Dec. 5, 2023 /PRNewswire/ -- Evolution Optiks Limited , a privately held company and forerunner in light field technology, announced today the successful completion of data collection in a US FDA-authorized clinical study to assess the safety and efficacy of its DeCon device for the evaluation of human vestibular disorders.

Key Points: 
  • CHRIST CHURCH, Barbados, Dec. 5, 2023 /PRNewswire/ -- Evolution Optiks Limited , a privately held company and forerunner in light field technology, announced today the successful completion of data collection in a US FDA-authorized clinical study to assess the safety and efficacy of its DeCon device for the evaluation of human vestibular disorders.
  • The study findings will be included in the application to the FDA to support the request for approval which the company currently expects to obtain in the first quarter of 2024.
  • "The results are very promising and we look forward to sharing the final analysis with the neuro-ophthalmological community."
  • Founded in 2014, Evolution Optiks Limited is commercializing an extensive and ongoing portfolio of innovation and is on track to revolutionizing how digital information is being consumed.

Evolution Optiks Successfully Completes Data Collection in Clinical Study of Neuro-Optical Testing Device

Retrieved on: 
Tuesday, December 5, 2023

CHRIST CHURCH, Barbados, Dec. 5, 2023 /PRNewswire/ -- Evolution Optiks Limited , a privately held company and forerunner in light field technology, announced today the successful completion of data collection in a US FDA-authorized clinical study to assess the safety and efficacy of its DeCon device for the evaluation of human vestibular disorders.

Key Points: 
  • CHRIST CHURCH, Barbados, Dec. 5, 2023 /PRNewswire/ -- Evolution Optiks Limited , a privately held company and forerunner in light field technology, announced today the successful completion of data collection in a US FDA-authorized clinical study to assess the safety and efficacy of its DeCon device for the evaluation of human vestibular disorders.
  • The study findings will be included in the application to the FDA to support the request for approval which the company currently expects to obtain in the first quarter of 2024.
  • "The results are very promising and we look forward to sharing the final analysis with the neuro-ophthalmological community."
  • Founded in 2014, Evolution Optiks Limited is commercializing an extensive and ongoing portfolio of innovation and is on track to revolutionizing how digital information is being consumed.

Rhaeos, Inc. Strengthens Leadership Team with Appointment of Dr. David Limbrick as Chief Medical Officer

Retrieved on: 
Tuesday, November 28, 2023

EVANSTON, Ill., Nov. 28, 2023 /PRNewswire/ -- Rhaeos, Inc., a clinical-stage medical device technology company dedicated to advancing diagnostic solutions for hydrocephalus patients, proudly welcomes David D. Limbrick, Jr., MD, PhD, as its new Chief Medical Officer (CMO).

Key Points: 
  • EVANSTON, Ill., Nov. 28, 2023 /PRNewswire/ -- Rhaeos, Inc., a clinical-stage medical device technology company dedicated to advancing diagnostic solutions for hydrocephalus patients, proudly welcomes David D. Limbrick, Jr., MD, PhD, as its new Chief Medical Officer (CMO).
  • Dr. Limbrick is currently a Professor at Virginia Commonwealth University, where he joined as the Chair of the Department of Neurosurgery in 2023.
  • "I am very excited to join the Rhaeos team after collaborating closely with them for the past two years," stated Dr. Limbrick.
  • The company looks forward to the continued advancement of their mission to have a global impact on neurosurgery and hydrocephalus management.

New report unveils groundbreaking opportunities for U.S. health care transformation

Retrieved on: 
Monday, November 27, 2023

BUFFALO, N.Y., Nov. 27, 2023 /PRNewswire/ -- "The Future of Health" — a forward-looking report jointly released by the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo and the Jacobs Institute, a nonprofit medical device innovation center — heralds massive potential for improving health care in the United States.

Key Points: 
  • While acknowledging systemic challenges, the report shines a spotlight on advancements and opportunities that promise to revolutionize health care.
  • The report is a follow-up to the 2017 The Future of Medicine report, which forecast disruptive changes wrought by emerging technologies and social movements on the health care landscape.
  • Life-extension science: Groundbreaking research is promising not just longer lives, but also late-in-life years filled with health, fulfillment and productivity.
  • Personal health technology: Cutting-edge devices and AI technologies are putting the power of health monitoring into the hands of individuals, enabling early action to prevent illness.

Pixyl receives FDA clearance for AI-powered brain MRI software Pixyl.Neuro™

Retrieved on: 
Monday, November 20, 2023

GRENOBLE, France, Nov. 20, 2023 /PRNewswire/ -- Pixyl has announced FDA 510(k) clearance for Pixyl.Neuro™, the next-generation AI software for brain MRI analysis that recently demonstrated enhanced detection rates up to 28%1.

Key Points: 
  • GRENOBLE, France, Nov. 20, 2023 /PRNewswire/ -- Pixyl has announced FDA 510(k) clearance for Pixyl.Neuro™, the next-generation AI software for brain MRI analysis that recently demonstrated enhanced detection rates up to 28%1.
  • Pixyl is an award-winning French medtech specializing in AI-powered MRI solutions to improve patient care.
  • "AI-driven MRI analysis opens the possibility of accessing previously unavailable clinically-relevant information to reinforce radiology workflows, especially in the context of neurological disorders."
  • We chose Pixyl to answer our routine practice needs based on their track-record of delivering high-quality brain MRI solutions.

TSI Group Joins Halma Group, Unveiling New Avenues for Growth

Retrieved on: 
Monday, November 20, 2023

Halma, a global group of life-saving technology companies, has successfully acquired the TSI Group, setting the stage for unprecedented opportunities in the Neuro, Spine, and Cardiothoracic markets.

Key Points: 
  • Halma, a global group of life-saving technology companies, has successfully acquired the TSI Group, setting the stage for unprecedented opportunities in the Neuro, Spine, and Cardiothoracic markets.
  • "This is an exciting development for the TSI Group, supporting our ambitions to expand and develop globally," says Danny Fishman, President at the TSI Group.
  • Leveraging Halma's expansive network of resources and focus on operational excellence, the TSI Group anticipates numerous new opportunities on the horizon.
  • The union of the TSI Group with Halma marks a pivotal moment for both organizations, creating a synergy that positions the TSI Group for sustained success and innovation in the dynamic field of medical technology.

TSI Group Joins Halma Group, Unveiling New Avenues for Growth

Retrieved on: 
Monday, November 20, 2023

Halma, a global group of life-saving technology companies, has successfully acquired the TSI Group, setting the stage for unprecedented opportunities in the Neuro, Spine, and Cardiothoracic markets.

Key Points: 
  • Halma, a global group of life-saving technology companies, has successfully acquired the TSI Group, setting the stage for unprecedented opportunities in the Neuro, Spine, and Cardiothoracic markets.
  • "This is an exciting development for the TSI Group, supporting our ambitions to expand and develop globally," says Danny Fishman, President at the TSI Group.
  • Leveraging Halma's expansive network of resources and focus on operational excellence, the TSI Group anticipates numerous new opportunities on the horizon.
  • The union of the TSI Group with Halma marks a pivotal moment for both organizations, creating a synergy that positions the TSI Group for sustained success and innovation in the dynamic field of medical technology.

GT Medical Technologies, Inc. Presents Use of GammaTile Therapy is Increasing in Time Across Several Brain Tumor Types at the 28th Annual Scientific Meeting and Education Day at the Society of Neuro-Oncology (SNO)

Retrieved on: 
Friday, November 17, 2023

TEMPE, Ariz., Nov. 17, 2023 /PRNewswire/ -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced an increase of clinical cases in the United States using its GammaTile® Therapy in patients diagnosed with several brain tumor types. The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.

Key Points: 
  • The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.
  • GammaTile has been used in over 1,000 patients with both newly diagnosed malignant brain tumors and recurrent brain tumors since 2019 and has been used in different tumor types, including glioblastoma, brain metastasis and meningioma.
  • Currently, GammaTile is sponsoring 4 clinical trials including a multi-institute registry trial (NCT0442738) that includes quality of life as a study metric.
  • GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) that delivers immediate radiation and eradicates brain tumor cells before they can replicate post-surgery while helping to protect healthy brain tissue.